The United States through the Food and Drugs Agency (FDA) has approved the generic version of Lenacapavir; a low-cost version of a twice-yearly HIV prevention shot, that is expected to boost the fight against HIV / AIDS.
Dr. Reddy’s Laboratories, the Indian maker of the generic version of lenacapavir, has confirmed the FDA approval of the jab.
The generic version of the drug will subsequently bring the cost of the HIV jab to 40 US Dollars which is equivalent KES. 5,195. The initial jab cost KES 7,800 ($60) per patient per year.
The jab will be made available to over 120 low-income countries through a collaboration between Unitaid, the African health research institute Wits RHI, and the Clinton Health Access Initiative (CHAI) and Dr. Reddy’s.
“This is an extraordinary milestone for global health. For too long, people in lower- and middle-income countries have had to wait a decade or more to access breakthrough medicines already available elsewhere,” Carmen Perez-Casas, Unitaid’s senior strategy lead for HIV and pandemic preparedness, has said.
The jab is however offered free of charge in select health facilities in Kenya.
Lenacapavir is offered twice a year as a HIV preexposure prophylaxis (PrEP) and has been hailed as a better alternative to daily pills especially for persons at a continuous risk of contracting HIV. of Saudi Arabia.*US Government Approves Low-Cost Anti-HIV Jab* .
The United States through the Food and Drugs Agency (FDA) has approved the generic version of Lenacapavir; a low-cost version of a twice-yearly HIV prevention shot, that is expected to boost the fight against HIV / AIDS.
Dr. Reddy’s Laboratories, the Indian maker of the generic version of lenacapavir, has confirmed the FDA approval of the jab.
The generic version of the drug will subsequently bring the cost of the HIV jab to 40 US Dollars which is equivalent KES. 5,195. The initial jab cost KES 7,800 ($60) per patient per year.
The jab will be made available to over 120 low-income countries through a collaboration between Unitaid, the African health research institute Wits RHI, and the Clinton Health Access Initiative (CHAI) and Dr. Reddy’s.
“This is an extraordinary milestone for global health. For too long, people in lower- and middle-income countries have had to wait a decade or more to access breakthrough medicines already available elsewhere,” Carmen Perez-Casas, Unitaid’s senior strategy lead for HIV and pandemic preparedness, has said.
The jab is however offered free of charge in select health facilities in Kenya.
Lenacapavir is offered twice a year as a HIV preexposure prophylaxis (PrEP) and has been hailed as a better alternative to daily pills especially for persons at a continuous risk of contracting HIV.
